Table 3 Systemic and topical anti-inflammatory therapy
Initial diagnosis of uveitis | Initial uveitis documentation | 5-year uveitis FU documentation | Cumulative until 5-year uveitis FU visit | |
|---|---|---|---|---|
n = 75 | n = 75 | n = 75 | n = 75 | |
DMARD (any), n (%) | 35 (46.7%) | 45 (60.0%) | 58 (77.3%) | 69 (92.0%) |
Combination of csDMARD and bDMARD, n (%) | 1 (1.3%) | 3 (4.0%) | 26 (34.7%) | - |
Number of DMARDs, mean (SD) | 0.5 (0.4) | 0.7 (0.7) | 1.2 (0.9) | - |
csDMARD (any), n (%) | 34 (45.3%) | 44 (58.7%) | 52 (69.3%) | 69 (92.0%) |
Methotrexate | 33 (44.0%) | 43 (57.3%) | 49 (65.3%) | 69 (92.0%) |
Cyclosporine | 0 (0.0%) | 1 (1.3%) | 3 (4.0%) | 6 (8.0%) |
Leflunomide | 1 (1.3%) | 1 (1.3%) | 0 (0.0%) | 1 (1.3%) |
Azathioprine | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 2 (2.7%) |
bDMARD (any), n (%) | 3 (4.0%) | 7 (9.3%) | 36 (48.0%) | 45 (60.0%) |
Adalimumab | 1 (1.3%) | 5 (6.7%) | 32 (42.7%) | 45 (60.0%) |
Infliximab | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 4 (5.3%) |
Tocilizumab | 0 (0.0%) | 0 (0.0%) | 1 (1.3%) | 4 (5.3%) |
Systemic corticosteroids, n (%) | 17 (22.7%) | 14 (18.7%) | 4 (5.3%) | 18 (24.0%) |
Topical corticosteroids, n (%) | - | 56 (74.7%) | 32 (42.7%) | 71 (94.7%) |